A296160 Stock Overview

A biotechnology company, engages in platform-based drug discovery and development activities. More details

A296160 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Does not have a meaningful market cap (₩86B)

Shareholders have been diluted in the past year

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Progen Co., Ltd. Competitors

Hyundai ADM Bio

KOSDAQ:A187660

₩72.0b

NanoEntek

KOSDAQ:A039860

₩112.2b

DreamCIS

KOSDAQ:A223250

₩71.0b

P&K Skin Research Center

KOSDAQ:A347740

₩63.8b

Price History & Performance

Summary of share price highs, lows and changes for Progen
Historical stock prices
Current Share Price	₩6,090.00
52 Week High	₩8,490.00
52 Week Low	₩4,515.00
Beta	0
1 Month Change	24.80%
3 Month Change	4.82%
1 Year Change	1.33%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	51.87%

Recent updates

Shareholder Returns

	A296160	KR Life Sciences	KR Market
7D	2.2%	-3.1%	2.1%
1Y	1.3%	37.9%	-7.6%

Return vs Industry: A296160 underperformed the KR Life Sciences industry which returned 37.9% over the past year.

Return vs Market: A296160 exceeded the KR Market which returned -7.6% over the past year.

Price Volatility

Is A296160's price volatile compared to industry and market?
A296160 volatility
A296160 Average Weekly Movement	7.5%
Life Sciences Industry Average Movement	5.3%
Market Average Movement	6.2%
10% most volatile stocks in KR Market	12.6%
10% least volatile stocks in KR Market	2.9%

Stable Share Price: A296160 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A296160's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1998	n/a	n/a	www.progen.co.kr

Progen Co., Ltd., a biotechnology company, engages in platform-based drug discovery and development activities. The company’s NTIG platform technology is used for the development of anti-cancer and immune disease treatments. It develops PG-102 for the treatment of obesity with T2DM to control blood sugar, improve metabolic function, and reduce weight in the gastrointestinal tract and adipocytes.

Progen Co., Ltd. Fundamentals Summary

How do Progen's earnings and revenue compare to its market cap?
A296160 fundamental statistics
Market cap	₩86.39b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A296160 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A296160 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A296160 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/04/29 02:12
End of Day Share Price	2025/04/29 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Progen Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Progen XKON:A296160 Stock Report